Masupirdine is an investigational new drug that is being evaluated for the treatment of agitation in Alzheimer's dementia.[1] It is a selective 5-HT6 receptor antagonist.[2]

References

  1. ^ "Masupirdine - Suven Life Sciences". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Nirogi R, Jayarajan P, Shinde A, Mohammed AR, Grandhi VR, Benade V, et al. (February 2023). "Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders". Biomolecules. 13 (2): 309. doi:10.3390/biom13020309. PMC 9953539. PMID 36830678.


No tags for this post.